Strata Critical Medical, Inc. (SRTA) Misses Q2 EPS by 9c ; Offers Guidance

Strata Critical Medical, Inc. (NASDAQ: SRTA) reported Q2 EPS of ($0.12), $0.09 worse than the analyst estimate of ($0.03). Revenue for the quarter came in at $72.5 million versus the consensus estimate of $66.99 million.

FY 2026 Outlook:-

Revenue between $285million to $295 million vs consensus $276.9 million.

For earnings history and earnings-related data on Strata Critical Medical, Inc. (SRTA) click here.

You May Also Be Interested In

• Medtronic jumps on earnings beat and raised guidance
• Chardan Assumes Rocket Pharmaceuticals (RCKT) at Buy
• Medtronic (MDT) Tops Q1 EPS by 6c, Beats on Revenue; Offers FY27 EPS Guidance